Anti-inflammatory effect of low molecular weight fucoidan from Saccharina japonica on atherosclerosis in apoE-knockout mice

Xu, Yingjie; Xu, Jie; Ge, Keli; Tian, Qing; Zhao, Peng; Guo, Yunliang

doi:10.1016/j.ijbiomac.2018.06.054

Cited by 48 publications

(34 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fucoidan oligosaccharide displays antihypertensive effects in renal vascular hypertensive rats, mediated through its ability to inhibit plasma angiotensin II production. In atherosclerosis models from apoE knockout mice, Xu et al demonstrated that LMWF can inhibit the inflammatory response and alter lipid metabolism by preventing macrophage development into foam cells and through the inhibition of macrophage migration [133].…”

Section: Non-classical Activitiesmentioning

confidence: 99%

Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies

et al. 2019

View full text Add to dashboard Cite

The marine acid polysaccharide fucoidan has attracted attention from both the food and pharmaceutical industries due to its promising therapeutic effects. Fucoidan is a polysaccharide that mainly consists of L-fucose and sulphate groups. Its excellent biological function is attributed to its unique biological structure. Classical activities include antitumor, antioxidant, anticoagulant, antithrombotic, immunoregulatory, antiviral and anti-inflammatory effects. More recently, fucoidan has been shown to alleviate metabolic syndrome, protect the gastrointestinal tract, benefit angiogenesis and bone health. This review focuses on the progress in our understanding of the biological activities of fucoidan, highlighting its benefits for the treatment of human disease. We hope that this review can provide some theoretical basis and inspiration for the product development of fucoidan.

show abstract

Section: Non-classical Activitiesmentioning

confidence: 99%

Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Fucoidan decreases the area of atherosclerotic plaques. It has been reported that apolipoprotein E-deficient (ApoE-/-) mice receiving an atherogenic diet with fucoidan show ameliorated atherosclerotic lesions in the aortas in a dose-dependent manner [13,14]. Additionally, spontaneously hyperlipidemia mice received high-fat diet supplemented with fucoidan exhibited inhibition in the development of AS [15].…”

Section: Fucoidanmentioning

confidence: 99%

“…Similarly, fucoidan from sea cucumber lowers the levels of TC and LDL-C and reduces the weight of adipose tissue in mice [20,21]. In addition, low molecular weight fucoidan diminishes TG and oxidized low-density lipoprotein (ox-LDL) levels, leading to stabilization of established atherosclerotic lesions [14]. The liver is an important organ participating in reverse cholesterol transport (RCT).…”

Section: Fucoidanmentioning

confidence: 99%

“…Recent studies have shown that fucoidan treatment reduces inflammatory cytokines in RAW264.7 macrophages and mice [25][26][27][28][29]. Low molecular weight fucoidan regulates the production and expression of inflammatory cytokines including IL-6, IL-10, phosphorylated c-Jun N-terminal kinase(p-JNK) and cyclin D1 and inhibits the inflammation associated with AS [14]. Fucoidan treatment decreases the expression of lectin-like ox-LDL receptor-1 (LOX-1) and the levels of pro-inflammatory cytokines 1L-1β, IL-6, tumor necrosis factor-alpha (TNF-α), vascular cell adhesion molecule-1 (VCAM-1),and intercellular cell adhesion molecule-1 (ICAM-1) in low-density lipoprotein receptor-deficient (LDLR-/-) mice [25], suggesting that fucoidan reduces AS in LDLR-/-mice by inhibiting the inflammatory response.…”

Section: Fucoidanmentioning

confidence: 99%

See 1 more Smart Citation

Current Research Landscape of Marine-Derived Anti-Atherosclerotic Substances

et al. 2020

View full text Add to dashboard Cite

Atherosclerosis is a chronic disease characterized by lipid accumulation and chronic inflammation of the arterial wall, which is the pathological basis for coronary heart disease, cerebrovascular disease and thromboembolic disease. Currently, there is a lack of low-cost therapeutic agents that effectively slow the progression of atherosclerosis. Therefore, the development of new drugs is urgently needed. The research and development of marine-derived drugs have gained increasing interest from researchers across the world. Many marine organisms provide a rich material basis for the development of atherosclerotic drugs. This review focuses on the latest technological advances in the structures and mechanisms of action of marine-derived anti-atherosclerotic substances and the challenges of the application of these substances including marine polysaccharides, proteins and peptides, polyunsaturated fatty acids and small molecule compounds. Here, we describe the theoretical basis of marine biological resources in the treatment of atherosclerosis.

show abstract

“…Fucoidan, fucose containing polysaccharides (FPs) belongs to a heterogeneous polysaccharide group obtained mainly from the extracellular medium with cellulose, hemicellulose, and alginate in brown seaweeds and primarily segregated by Kylin in 1993 [1,2]. In recent years FPs has acquired much curiosity in functional food and pharmaceutical industries because of its abundant bioactive properties such as anti-cancer/anti-tumor [3,4], anti-viral, anti-oxidant, anti-coagulant, anti-diabetic, anti-obesity, anti-bacterial [5] and therapeutic potential against injuries [6,7]. Different studies exhibited that the structure of FPs varies from each other due to the position of glycosidic bonds, branches of the chain, relative molecular weight and sulfate group substitutions, which are caused by extraction methods, type of species, region of growth, time of harvesting and other environmental and geographical factors [8,9].…”

Section: Introductionmentioning

confidence: 99%

Characterization of L-fucose isomerase from Paenibacillus rhizosphaerae to produce L-fuculose from hydrolyzed fucoidan and commercial fucose

Iqbal¹,

Riaz²,

Mahmood³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background L-fuculose is an expensive and rare sugar used against different kinds of diseases such as HIV, anti-cancer, anti-viral, Hepatitis-B, human lysosomal disease (fucosidosis), and cardio-protective drugs. The enzymatic way of converting L-fucose into L-fuculose would be an effective method with great industrial applications. The purpose of this research is to introduce a high production of L-fuculose from cheap and natural sources (fucoidan) and commercially source (Sigma-Aldrich) by a recombinant enzyme L-fucose isomerase from Paenibacillus rhizosphaerae (Pa-LFI).Results Fucose containing polysaccharide (FPs) called fucoidan was extracted, hydrolyzed and characterized by U. pinnatifida for enzymatic production of L-fuculose. The FPs provide 35.9% of fucose along with few other monosaccharides. Pa-LFI was characterized and purified with a single band at 65 kDa. It showed an activity of 104.5 U mg -1 and exhibited as a hexamer with native molecular mass 396 kDa. The maximum activity for recombinant Pa-LFI was detected at pH 6.5 and 50 °C in 1 mM of Mn 2+ . The melting temperature observed 75 °C and half-life at 50 °C was 12.6 h. The isomerizing activity of Pa-LFI with aldose substrate (L-fucose) was higher exposing K m , k cat and k cat / K m 86.2 mM, 32831 min -1 and 335 min -1 mM -1 respectively. The conversion ratio of L-fuculose from 100 g L -1 of FPs and commercial fucose after the equilibrium state was about 6% (5.6 g L -1 ) and 30% (30.2 g L -1 ) respectively.Conclusion Pa-LFI catalyzed the reaction to convert L-fucose into L-fuculose. The enzyme will be helpful in the production of L-fuculose with an efficient and simple method without producing any by-product.

show abstract

Anti-inflammatory effect of low molecular weight fucoidan from Saccharina japonica on atherosclerosis in apoE-knockout mice

Cited by 48 publications

References 47 publications

Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies

Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies

Current Research Landscape of Marine-Derived Anti-Atherosclerotic Substances

Characterization of L-fucose isomerase from Paenibacillus rhizosphaerae to produce L-fuculose from hydrolyzed fucoidan and commercial fucose

Contact Info

Product

Resources

About